WO2008011073A3 - Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof - Google Patents
Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof Download PDFInfo
- Publication number
- WO2008011073A3 WO2008011073A3 PCT/US2007/016312 US2007016312W WO2008011073A3 WO 2008011073 A3 WO2008011073 A3 WO 2008011073A3 US 2007016312 W US2007016312 W US 2007016312W WO 2008011073 A3 WO2008011073 A3 WO 2008011073A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- analogs
- derivatives
- androgen receptor
- receptor modulators
- selective androgen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C335/18—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007275737A AU2007275737A1 (en) | 2006-07-19 | 2007-07-19 | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
JP2009520822A JP2009543872A (en) | 2006-07-19 | 2007-07-19 | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
CA002658098A CA2658098A1 (en) | 2006-07-19 | 2007-07-19 | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
BRPI0713200-0A BRPI0713200A2 (en) | 2006-07-19 | 2007-07-19 | selective androgen receptor modulators, their analogues and derivatives, and their uses |
EP07810587A EP2040709A2 (en) | 2006-07-19 | 2007-07-19 | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
EA200900203A EA200900203A1 (en) | 2006-07-19 | 2007-07-19 | ELECTORAL MODULATORS OF ANDROGENS RECEPTOR, THEIR ANALOGUES, DERIVATIVES AND APPLICATIONS |
MX2009000714A MX2009000714A (en) | 2006-07-19 | 2007-07-19 | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof. |
IL196534A IL196534A0 (en) | 2006-07-19 | 2009-01-15 | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83198806P | 2006-07-19 | 2006-07-19 | |
US83188006P | 2006-07-19 | 2006-07-19 | |
US60/831,988 | 2006-07-19 | ||
US60/831,880 | 2006-07-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008011073A2 WO2008011073A2 (en) | 2008-01-24 |
WO2008011073A3 true WO2008011073A3 (en) | 2008-10-23 |
Family
ID=38957352
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/016312 WO2008011073A2 (en) | 2006-07-19 | 2007-07-19 | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
PCT/US2007/016311 WO2008011072A2 (en) | 2006-07-19 | 2007-07-19 | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/016311 WO2008011072A2 (en) | 2006-07-19 | 2007-07-19 | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (2) | US8110562B2 (en) |
EP (2) | EP2041077A2 (en) |
JP (2) | JP2009543872A (en) |
KR (2) | KR20090035707A (en) |
AR (1) | AR063208A1 (en) |
AU (2) | AU2007275737A1 (en) |
BR (2) | BRPI0713200A2 (en) |
CA (2) | CA2658096A1 (en) |
EA (2) | EA200900203A1 (en) |
IL (2) | IL196533A0 (en) |
MX (2) | MX2009000714A (en) |
WO (2) | WO2008011073A2 (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2824517A1 (en) * | 2005-11-28 | 2007-05-31 | Gtx, Inc. | Nuclear receptor binding agents |
US9409856B2 (en) | 2005-11-28 | 2016-08-09 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US8158828B2 (en) * | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
US8546451B2 (en) * | 2005-11-28 | 2013-10-01 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US8637706B2 (en) | 2005-11-28 | 2014-01-28 | Gtx, Inc. | Nuclear receptor binding agents |
US7550505B2 (en) * | 2006-07-24 | 2009-06-23 | University Of Delaware | Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal |
US7834051B2 (en) | 2007-08-07 | 2010-11-16 | Takeda Pharmaceutical Company Limited | Cyclic amine compounds |
AU2008296136A1 (en) | 2007-09-07 | 2009-03-12 | Bionovo. Inc. | Estrogenic extracts of Scuttelaria barbata D. Don of the Labiatae Family and uses thereof |
EP2222323A4 (en) | 2007-11-19 | 2012-07-25 | Bionovo Inc | A process of making purified extract of scutellaria barbata d. don |
EP2260028B1 (en) | 2008-02-22 | 2014-05-07 | Radius Health, Inc. | Selective androgen receptor modulators |
US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
US20110105608A1 (en) * | 2008-03-21 | 2011-05-05 | Northeastern University | Modulators of nuclear receptor co-regulatory protein binding |
ITBO20090078A1 (en) * | 2009-02-13 | 2010-08-14 | Consiglio Nazionale Ricerche | COMPOUNDS FOR TREATING TUMOR TO THE PROSTATE AND PROCEDURES FOR THEIR SYNTHESIS |
US9427418B2 (en) | 2009-02-23 | 2016-08-30 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US9624161B2 (en) | 2009-02-23 | 2017-04-18 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
EP2424853B1 (en) * | 2009-04-10 | 2018-09-19 | Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (I.R.S.T.) S.R.L. | Non-steroidal compounds for androgen receptor modulation, processes for the preparation and uses thereof |
ITBO20090235A1 (en) * | 2009-04-10 | 2010-10-11 | Consiglio Nazionale Ricerche | COMPOUNDS FOR TREATING TUMOR TO THE PROSTATE AND PROCEDURES FOR THEIR SYNTHESIS |
US8450374B2 (en) * | 2009-06-29 | 2013-05-28 | University Of Delaware | Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal |
US8277459B2 (en) | 2009-09-25 | 2012-10-02 | Tarsus Medical Inc. | Methods and devices for treating a structural bone and joint deformity |
US8791158B2 (en) * | 2010-01-11 | 2014-07-29 | Gtx, Inc. | Methods of treating meibomian gland dysfunction |
GB201000685D0 (en) | 2010-01-15 | 2010-03-03 | Glaxo Group Ltd | Novel compounds |
US8652141B2 (en) | 2010-01-21 | 2014-02-18 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
EP2531029B1 (en) | 2010-02-04 | 2016-10-19 | Radius Health, Inc. | Selective androgen receptor modulators |
AU2011223706A1 (en) * | 2010-03-05 | 2012-09-20 | Baylor Research Institute | Involvement of androgen/androgen receptor pathway in Fabry disease |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
SI2568806T1 (en) | 2010-05-12 | 2016-09-30 | Radius Health, Inc. | Therapeutic regimens |
US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
FI20105806A0 (en) | 2010-07-15 | 2010-07-15 | Medeia Therapeutics Ltd | New arylamide derivatives with antiandrogenic properties |
AU2011312490B2 (en) | 2010-09-28 | 2015-06-25 | Radius Pharmaceuticals, Inc. | Selective androgen receptor modulators |
WO2013104829A1 (en) | 2012-01-13 | 2013-07-18 | Medeia Therapeutics Ltd | Novel arylamide derivatives having antiandrogenic properties |
WO2013104831A1 (en) | 2012-01-13 | 2013-07-18 | Medeia Therapeutics Ltd | Arylamide derivatives having antiandrogenic properties |
EP2802563B1 (en) | 2012-01-13 | 2017-06-07 | Aranda Pharma Ltd | Novel heteroarylamide derivatives having antiandrogenic properties |
ES2668300T3 (en) | 2012-05-02 | 2018-05-17 | Boehringer Ingelheim International Gmbh | 3-haloamidine substituted SSAO inhibitors and uses thereof |
JP6401702B2 (en) | 2012-09-07 | 2018-10-10 | ザ・ガバナーズ・オブ・ザ・ユニバーシティー オブ・アルバータ | Methods and compositions for diagnosis of inflammatory liver disease |
US20140274979A1 (en) * | 2013-03-13 | 2014-09-18 | Golden Biotechnology Corporation | Method for the treatment of fatty liver disease |
WO2015102996A1 (en) * | 2013-12-31 | 2015-07-09 | Grasso Frank J | Extremely high loading dose |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
SI3122426T1 (en) | 2014-03-28 | 2023-04-28 | Duke University | Treating breast cancer using selective estrogen receptor modulators |
KR101597327B1 (en) | 2014-04-24 | 2016-02-24 | 동아에스티 주식회사 | Oxazolidine-based compound and selective androgen receptor agonists comprising the same |
JOP20180072A1 (en) | 2014-09-11 | 2019-01-30 | Lilly Co Eli | Treatment of androgen deprivation therapy associated symptoms |
US10441570B2 (en) | 2015-04-21 | 2019-10-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) Ligands and methods of use thereof |
US10865184B2 (en) | 2015-04-21 | 2020-12-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10654809B2 (en) | 2016-06-10 | 2020-05-19 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
MX2017013565A (en) | 2015-04-21 | 2018-02-19 | Gtx Inc | Selective androgen receptor degrader (sard) ligands and methods of use thereof. |
US10035763B2 (en) | 2015-04-21 | 2018-07-31 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10017471B2 (en) | 2015-04-21 | 2018-07-10 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10806720B2 (en) | 2015-04-21 | 2020-10-20 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
KR20170140291A (en) | 2015-04-21 | 2017-12-20 | 지티엑스, 인코포레이티드 | Selective androgen receptor dissociation (SARD) ligands and methods for their use |
US9834507B2 (en) | 2015-04-21 | 2017-12-05 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10093613B2 (en) | 2015-04-21 | 2018-10-09 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US11230523B2 (en) | 2016-06-10 | 2022-01-25 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
DK3474841T3 (en) | 2016-06-22 | 2022-05-09 | Ellipses Pharma Ltd | PROCEDURES FOR THE TREATMENT OF AR + BREAST CANCER |
US11167007B2 (en) | 2016-08-04 | 2021-11-09 | City Of Hope | FOXM1 modulators and uses thereof |
KR20230109795A (en) | 2017-01-05 | 2023-07-20 | 래디어스 파마슈티컬스, 인코포레이티드 | Polymorphic forms of rad1901-2hcl |
WO2019025153A1 (en) | 2017-07-31 | 2019-02-07 | Bayer Cropscience Aktiengesellschaft | Use of substituted n-sulfonyl-n'-aryl diaminoalkanes and n-sulfonyl-n'-heteroaryl diaminoalkanes or salts thereof for increasing the stress tolerance in plants |
US11707449B2 (en) | 2017-10-27 | 2023-07-25 | St. Jude Children's Research Hospital, Inc. | Methods and formulations for treatment of spinobulbar muscular atrophy |
US20200392103A1 (en) | 2017-11-23 | 2020-12-17 | Basf Se | Herbicidal pyridylethers |
BR112020008084B1 (en) | 2017-11-23 | 2023-11-14 | Basf Se | PHENYL ETHERS, HERBICIDAL COMPOSITION, PROCESS FOR PREPARING ACTIVE COMPOSITIONS, METHOD FOR CONTROLLING UNWANTED VEGETATION AND USE OF PHENYL ETHERS |
EP3817821A1 (en) | 2018-07-04 | 2021-05-12 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad 1901-2hcl |
WO2023011596A1 (en) * | 2021-08-05 | 2023-02-09 | 中国药科大学 | Amide compound and use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2684965A (en) * | 1950-08-10 | 1954-07-27 | Abbott Lab | Aminoalkylpiperidines |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB798410A (en) | 1956-01-18 | 1958-07-23 | Bofors Ab | N-alkyl-tetrahydroquinaldinic acid amides |
US6995284B2 (en) * | 2000-08-24 | 2006-02-07 | The University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
ITMI20012060A1 (en) | 2001-10-05 | 2003-04-05 | Recordati Chem Pharm | NEW N-ACYLATED HETEROCYCLES |
-
2007
- 2007-07-19 BR BRPI0713200-0A patent/BRPI0713200A2/en not_active Application Discontinuation
- 2007-07-19 WO PCT/US2007/016312 patent/WO2008011073A2/en active Application Filing
- 2007-07-19 CA CA002658096A patent/CA2658096A1/en not_active Abandoned
- 2007-07-19 KR KR1020097003234A patent/KR20090035707A/en not_active Application Discontinuation
- 2007-07-19 JP JP2009520822A patent/JP2009543872A/en not_active Withdrawn
- 2007-07-19 US US11/826,987 patent/US8110562B2/en not_active Expired - Fee Related
- 2007-07-19 WO PCT/US2007/016311 patent/WO2008011072A2/en active Application Filing
- 2007-07-19 MX MX2009000714A patent/MX2009000714A/en not_active Application Discontinuation
- 2007-07-19 US US11/826,985 patent/US20090156614A1/en not_active Abandoned
- 2007-07-19 EA EA200900203A patent/EA200900203A1/en unknown
- 2007-07-19 EA EA200900202A patent/EA200900202A1/en unknown
- 2007-07-19 KR KR1020097003232A patent/KR20090030345A/en not_active Application Discontinuation
- 2007-07-19 BR BRPI0713198-4A patent/BRPI0713198A2/en not_active Application Discontinuation
- 2007-07-19 EP EP07836135A patent/EP2041077A2/en not_active Withdrawn
- 2007-07-19 AU AU2007275737A patent/AU2007275737A1/en not_active Abandoned
- 2007-07-19 CA CA002658098A patent/CA2658098A1/en not_active Abandoned
- 2007-07-19 MX MX2009000715A patent/MX2009000715A/en not_active Application Discontinuation
- 2007-07-19 EP EP07810587A patent/EP2040709A2/en not_active Withdrawn
- 2007-07-19 JP JP2009520821A patent/JP2009543871A/en not_active Withdrawn
- 2007-07-19 AU AU2007275736A patent/AU2007275736A1/en not_active Abandoned
- 2007-07-20 AR ARP070103235A patent/AR063208A1/en unknown
-
2009
- 2009-01-15 IL IL196533A patent/IL196533A0/en unknown
- 2009-01-15 IL IL196534A patent/IL196534A0/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2684965A (en) * | 1950-08-10 | 1954-07-27 | Abbott Lab | Aminoalkylpiperidines |
Non-Patent Citations (1)
Title |
---|
BEADLE C.D.: "1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, nove ard selective norepinephrine re-uptake inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 15, no. 20, 2005, pages 4432 - 4437, XP005064624 * |
Also Published As
Publication number | Publication date |
---|---|
US8110562B2 (en) | 2012-02-07 |
BRPI0713198A2 (en) | 2012-10-16 |
AR063208A1 (en) | 2009-01-14 |
IL196533A0 (en) | 2009-11-18 |
EA200900202A1 (en) | 2009-06-30 |
WO2008011073A2 (en) | 2008-01-24 |
EP2041077A2 (en) | 2009-04-01 |
EA200900203A1 (en) | 2009-06-30 |
MX2009000714A (en) | 2009-07-27 |
WO2008011072A3 (en) | 2008-06-05 |
KR20090030345A (en) | 2009-03-24 |
WO2008011072A2 (en) | 2008-01-24 |
CA2658098A1 (en) | 2008-01-24 |
KR20090035707A (en) | 2009-04-10 |
US20110077221A1 (en) | 2011-03-31 |
BRPI0713200A2 (en) | 2012-04-10 |
CA2658096A1 (en) | 2008-01-24 |
JP2009543872A (en) | 2009-12-10 |
JP2009543871A (en) | 2009-12-10 |
AU2007275736A1 (en) | 2008-01-24 |
MX2009000715A (en) | 2009-07-22 |
AU2007275737A1 (en) | 2008-01-24 |
IL196534A0 (en) | 2009-11-18 |
EP2040709A2 (en) | 2009-04-01 |
US20090156614A1 (en) | 2009-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008011073A3 (en) | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof | |
WO2006015259A3 (en) | Compounds and compositions as modulators of steroid hormone nuclear receptors | |
WO2006066011A3 (en) | Compounds and compositions as modulators of steroidal receptors and calcium channel activities | |
HK1166983A1 (en) | Solid forms comprising compounds for the treatment of diseases or disorders, compositions thereof, and use therewith | |
GB2443287B (en) | Methods, compositions and formulations for the treatment of thyroid eye disease | |
TWI369987B (en) | New pharmaceutical compositions for the treatment of hyper-proliferative disorders | |
IL177346A0 (en) | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer | |
HK1198922A1 (en) | Compositions for treating or preventing oxalate-related disease | |
PL1978993T3 (en) | Compositions and methods for treating cancer based on human fzd receptors | |
IL233634A0 (en) | Methods, compositions, and kits for the treatment of medical conditions | |
WO2007092065A3 (en) | Compounds and compositions as lxr modulators | |
WO2006058236A3 (en) | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease | |
EP1971372A4 (en) | Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same | |
EP1622589A4 (en) | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders | |
ZA200607433B (en) | Methods and compositions for the treatment of gastroin-testinal disorders | |
PL1761266T3 (en) | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | |
EP1737482A4 (en) | Compositions and methods for treating diseases | |
EP1827407A4 (en) | Methods, assays and compositions for treating retinol-related diseases | |
MX293459B (en) | Emulsifier composition for shortening | |
WO2007025303A3 (en) | Non-steroidal antiandrogens | |
WO2008112290A3 (en) | Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer | |
WO2005077124A3 (en) | Compounds and compositions as lxr modulators | |
EP1968645A4 (en) | Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses | |
WO2008069976A3 (en) | Compounds and methods for enzyme-mediated tumor imaging and therapy | |
WO2008103431A3 (en) | Dnai - liposomes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2007810587 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07810587 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007275737 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2658098 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009520822 Country of ref document: JP Ref document number: MX/A/2009/000714 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007275737 Country of ref document: AU Date of ref document: 20070719 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 525/KOLNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097003232 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200900203 Country of ref document: EA |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
ENP | Entry into the national phase |
Ref country code: GE Ref document number: GE P |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11566 Country of ref document: GE |
|
ENP | Entry into the national phase |
Ref document number: PI0713200 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090119 |